Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.49 |
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA4 | P22748 | 5/20 | 0.49 |
| ▸ | CA7 | P43166 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349588 | 1.00 | KDM4E (0.61) | KDM4EABL1LMNADPP4DPP8 | |
| SCHEMBL785166 | 1.00 | KDM4E (0.61) | KDM4EABL1LMNADPP4DPP8 | |
| Hydrochloric Acid SCHEMBL23167687 | 0.99 | KDM4E (0.60) | KDM4EABL1LMNADPP4DPP8 | |
| Hydrochloric Acid SCHEMBL23167691 | 0.99 | KDM4E (0.60) | KDM4EABL1LMNADPP4DPP8 | |
| SCHEMBL1351273 | 0.91 | KDM4E (0.68) | KDM4EABL1LMNADPP4DPP8 | |
| SCHEMBL7250781 | 0.90 | KDM4E (0.58) | KDM4EABL1LMNADPP4DPP8 | |
| Hydrochloric Acid SCHEMBL2001717 | 0.90 | KDM4E (0.67) | KDM4EABL1LMNADPP4DPP8 | |
| Hydrochloric Acid SCHEMBL29773190 | 0.90 | KDM4E (0.67) | KDM4EABL1LMNADPP4DPP8 | |
| Hydrochloric Acid SCHEMBL2121386 | 0.90 | KDM4E (0.67) | KDM4EABL1LMNADPP4DPP8 | |
| SCHEMBL4479608 | 0.88 | KDM4E (0.56) | KDM4EABL1LMNADPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | claimed |
| EP-2205601-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | claimed |
| WO-2009050199-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | claimed |
| JP-4202421-B2 | — | — | 2008-12-24 | — | — | JP | claimed |
| EP-0912520-B1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | AVENTIS PHARM PROD INC (US) | 2003-05-07 | — | — | EP | claimed |
| US-6559313-B2 | Adenosine derivatives such as (1S,2R,3S,4R)-2,3-dihydroxy-4-(6-(1-(4-trifluormethylpyridin-2-yl)pyrrolidin-3(S)-yl-amino)purin-9-yl)cyclopentanecarboxylic acid isopropylamide | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-06 | — | — | US | claimed |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-25 | — | — | US | claimed |
| JP-2000514801-A | — | — | 2000-11-07 | — | — | JP | claimed |
| WO-2000023447-B1 | ADENOSINE ANALOGUES HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC ANTILIPOLYTIC PROPERTIES | AVENTIS PHARM PROD INC (US) | 2000-06-29 | — | — | WO | claimed |
| WO-2000023447-A1 | ADENOSINE ANALOGUES HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC ANTILIPOLYTIC PROPERTIES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-04-27 | — | — | WO | claimed |
| EP-0912520-A4 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE POULENC RORER PHARMA (US) | 1999-10-06 | — | — | EP | claimed |
| EP-0912520-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1998001426-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-15 | — | — | WO | claimed |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-26 | — | — | US | disclosed |
| WO-2021067805-A1 | OXALAMIDE HETEROBYCYCLIC COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | disclosed |
| WO-2000023447-A1 | ADENOSINE ANALOGUES HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC ANTILIPOLYTIC PROPERTIES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0912520-A4 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE POULENC RORER PHARMA (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0912520-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001426-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | ADORA2A, ADORA1, ADORA3 | KDM4E 3737/4885ABL1 1123/4885LMNA 2449/4885 |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KDM4E 3761/4885ABL1 1538/4885LMNA 2339/4885 |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | HMGCR, TGFB1, APOB | KDM4E 2056/4885ABL1 2759/4885LMNA 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.